Psyence Biomedical Ltd. (PBM) jumped 41.53 percent to $8.31, gaining $2.44 on Friday, after the company highlighted increasing regulatory attention toward ibogaine and its therapeutic potential.
The stock is currently trading at $8.31, compared to its previous close of $5.87 on the Nasdaq. During the session, it reached a high of $9.83 and a low of $8.04, with trading volume surging to 36,685,321 shares, well above its average volume of 1,055,914.
The move follows reports that the U.S. administration is preparing an executive order to evaluate the safety and therapeutic potential of ibogaine, a compound being studied for treating PTSD, addiction, and other neurological conditions. The development signals growing interest in regulated research for psychedelic-based therapies.
Psyence Biomedical's 52-week range is $1.92 to $468.36.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.